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Anticoagulant drugs reduce the risk of venous thromboembolic events after total hip and knee arthroplasty. However, the use of
current drugs, such as low molecular weight heparins, is hampered by their subcutaneous route of administration.
Theuseof vitamin K antagonists ishampered by therequirement for routinecoagulation monitoring and dosetitrationto provide
eﬀective anticoagulation without an increased risk of bleeding and numerous food and drug interactions. Clearly, there is a need
for new oral, ﬁxed-dose anticoagulant drugs that do not require coagulation monitoring, while demonstrating similar or better
eﬃcacy and safety proﬁles when compared with current agents.
1.Introduction
In 2007, the annual number of total hip and knee arthro-
plasties (THAs and TKAs) in the US was 250,000 and
500,000, respectively [1]. These numbers are expected to
increase to 572,000 and 3.48 million for primary THA and
TKA, respectively, between 2005 and 2030 [1]. Orthopaedic
surgeons and internists are fully aware of these expected
increases in the number of elective THAs/TKAs.
The types of patients undergoing THA/TKA are con-
sistent and the risks of surgery are well characterized.
AntibioticprophylaxisforTHA/TKAisestimatedtodecrease
the relative risk of wound infection by 81% compared
with no prophylaxis [2]. Similarly, the appropriate use of
anticoagulant drugs has been shown to reduce the risk
of venous thromboembolism (VTE) after THA/TKA, and
guidelines recommend their routine use after this type of
surgery. Without prophylaxis, the incidence of venographic
deep vein thrombosis (DVT) and of pulmonary embolism
(PE) after THA are 42–57% and 0.9–28%, respectively [3].
The index event usually occurs at a mean of 21.5 (standard
deviation 22.5) days after surgery—typically after hospital
discharge [4]. The risk of venographic DVT and PE after
TKA is 41–85% and 1.5–10%, respectively [3]. Clinical
symptomatic events usually occur at a mean of 9.7 days
after TKA and 21.5 days after THA [4], with 75% occurring
after a median hospital stay of 5 days for THA. The current
trend is towards much shorter hospital stays, with a mean
of less than 3 days for THA and TKA at Roper Hospital
(Charleston, SC, USA) in 2009, meaning that the vast
majority of symptomatic events will occur on an outpatient
basis and, therefore, prophylaxis is mainly an outpatient
issue.
The American College of Chest Physicians (ACCP)
guidelines recommend prophylaxis with anticoagulants for
a minimum of 10 days and up to 35 days after THA
to reduce the risk of VTE (Grade 1A). After TKA, the
ACCP recommends prophylaxis with anticoagulants for at
least 10 days (Grade 1A) and suggests up to 35 days in
some patients (Grade 2B) [3]. Options include vitamin K
antagonists (VKAs), such as warfarin, low molecular weight
heparins (LMWHs), such as enoxaparin, and the synthetic
pentasaccharide fondaparinux. Although the antiplatelet
acetylsalicylic acid (ASA) is considered by some clinicians
to have a role in the prevention of PE, its use alone for
thromboprophylaxis is not recommended by the ACCP.
The American Academy of Orthopaedic Surgeons
(AAOS) has published guidelines strictly on the prevention2 Thrombosis
of PE, not DVT prophylaxis, recommending that patients
at standard risk of both PE and major bleeding should
be considered for one of the prophylactic agents evalu-
ated in their guideline, including ASA, LMWHs, synthetic
pentasaccharides and warfarin. Those at increased (above
standard) risk of PE and standard risk of major bleeding
should be considered for one of the prophylactic agents
evaluated in their guideline, including LMWHs, synthetic
pentasaccharides, and warfarin. Patients at standard risk
of PE and at increased risk of major bleeding should
be considered for prophylaxis with ASA or warfarin, as
evaluated in their guideline [5]. However, they fail to provide
any deﬁnitions or guidelines regarding what patients are at
increased risk of bleeding and increased risk of PE, or the
standard risk of bleeding and PE.
Although the AAOS does not speciﬁcally give guid-
ance on the prevention of DVT after THA/TKA, DVT
prophylaxis is as important as the prevention of PE
because after an initial DVT (any cause), patients
have a 10% risk of recurrent VTE after 1 year [6].
The risk of recurrence is ≤3% per year in patients
with transient risk factors (such as recent surgery) [7].
Following an episode of DVT, there is an approximate 24%
risk of postthrombotic syndrome after 3 years [6]. Of all
untreated initial calf vein thrombi (distal DVT), 20% extend
proximally [8]. Moreover, thrombus resolution is slower and
postthrombotic syndrome is more severe after proximal than
distal DVT [9].
The clinical challenges that orthopaedic surgeons,
internists, and clinicians face are that current anticoagulants
are administered subcutaneously or require monitoring and
dose titration to provide eﬀective anticoagulation without
increasing bleeding risk. More eﬀective and convenient
alternative anticoagulants, which can be given at ﬁxed doses
without routine coagulation monitoring, could improve
current clinical practice [10, 11]. New oral anticoagulant
drugs are being developed that address these issues, while
having similar or better eﬃcacy and safety proﬁles when
compared with current agents.
This paper will review the unmet clinical needs with
current agents, discuss the new classes of oral agents, present
data on the new oral agents currently available in the
European Union (EU) and other countries, and discuss how
these agents might meet the needs of orthopaedic surgeons
and internists in VTE prophylaxis.
2.CurrentAnticoagulantRegimens
2.1. Parenteral Anticoagulants. Although unfractionated
heparins (UFHs) have been available since the early 1930s,
studies in the 1970s demonstrated that they prevented VTE
and fatal PE in patients undergoing surgery [12, 13]. UFHs
act at several points of the coagulation cascade (Figure 1).
Parenteral LMWHs, which emerged in the early 1980s, also
actatseverallevelsofthecoagulationcascade[14](Figure 1).
During the 1990s, a comprehensive series of studies
demonstrated the clinical value of LMWHs in reducing the
risk of VTE [15]( Table 1). Compared with UFHs, LMWHs
oﬀered a convenient solution—they were available as ﬁxed
doses, did not require routine coagulation monitoring or
dose adjustment [14], and led to clinically signiﬁcant reduc-
tions in the number of venous thromboembolic events [15].
The diﬀerent LMWHs are created chemically or by depoly-
merization of UFH. LMWHs target both Factor Xa and
FactorIIa(thrombin)[14].TheratioofFactorXa:FactorIIa
inhibition diﬀers between the diﬀerent available LMWHs
and these ratios are considered to be related to safety and
eﬃcacy (the greater the level of Factor Xa inhibition, the
greatertheeﬃcacy[16]becauseFactorXaisgeneratedearlier
in the coagulation cascade than thrombin). The ratio of
Factor Xa : Factor IIa inhibition ranges from 2:1 to 4:1 for
the diﬀerent LMWHs in current use, compared with 1:1 for
UFH [14], indicating that antithrombotic activity may be
higher when using LMWHs, without the increased risk of
bleeding.
Fondaparinux (2.5mg once daily), a subcutaneously
administered, indirect Factor Xa inhibitor (Figure 1), was
more eﬀective than enoxaparin (30mg every 12 hours
after TKA and 40mg once daily after THA) in reducing
the risk of VTE [17, 18]. The timing of fondaparinux
administrationaﬀectedtheeﬃcacyandincidenceofbleeding
events after THA/TKA: major bleeding was signiﬁcantly
higher in patients who received their ﬁrst dose <6h o u r sa f t e r
skin closure (3.2%) than in those where the ﬁrst dose was
delayed to ≥6h o u r s( 2 . 1 % ,P = .045). This eﬀect was more
evident in patients who weighed <50kg, those >75 years of
age, and those with moderate renal impairment [19].
It is important to note that bleeding events are
always likely after surgery—aﬀecting approximately 2.4% of
patients even when no anticoagulants are used [20]—and
anticoagulants do not increase bleeding risk when adminis-
tered correctly with regards to dosage, timing and concomi-
tant use of other agents that aﬀect bleeding (such as non-
steroidal anti-inﬂammatory drugs). LMWHs oﬀer a good
balance, by reducing the number of venous thromboembolic
eventswhilemaintaining lowbleeding rates.However,recent
studies have highlighted that only approximately half of
patients in the US receive prophylaxis after THA/TKA at the
timing, duration and intensity recommended by the ACCP
[3,21].Worldwide,59%ofsurgicalpatients(undergoingany
type of surgery) at risk of VTE receive ACCP-recommended
prophylaxis [22]. Furthermore, the duration of prophylaxis
is often shorter than the period in which thromboembolic
events occur after surgery [4]. Possible reasons for this
are that surgeons may not be aware of the substantial
postdischarge risk of thromboembolic events, cost, lack of
convenience, and need for monitoring.
2.2.OralAntithrombotics. Developedinthe1950s,theVKAs,
such as warfarin, indirectly inhibit the production of several
coagulation factors (Figure 1). Although recommended in
the ACCP guidelines, studies have shown that warfarin is
not as eﬀective as parenteral anticoagulants in reducing the
venographic DVT incidence [15]( Table 1). Although it is an
oral agent, warfarin is less convenient than parenteral antico-
agulants,mainlyduetotheneedforfrequentmonitoringand
dose adjustments, and food and drug interactions. Owing to
its slow onset of action, it can take 2–4 days for a therapeuticThrombosis 3
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Figure 1: Coagulation cascade: where anticoagulants act. AT, antithrombin.
Table 1: Deep vein thrombosis frequencies following prophylaxis with diﬀerent agents after total hip and knee arthroplasties [15].
DVT frequency after total hip arthroplasty DVT frequency after total knee arthroplasty
Prevalence (%) Relative risk reduction (%) Prevalence (%) Relative risk reduction (%)
Acetylsalicylic acid 40.2 26 56.0 13
Low molecular weight heparins 16.1 70 30.6 52
Warfarin 22.1 59 46.8 27
DVT, deep vein thrombosis.
international normalized ratio (INR; range: 2–3 [3]) to be
reached. Warfarin has an unpredictable pharmacological
proﬁle and dosing needs to be individualized. With a narrow
window for safety and eﬃcacy, coagulation monitoring is
essential to ensure that patients remain within the INR range
after discharge; patients have to be taught how to monitor
their INR and take the correct dose at home or frequently
attend clinics or a primary care physician. Furthermore,
warfarin has many food and drug interactions that may
potentiate or inhibit its action, which may be problematic
in patients taking concomitant medications for comorbid
conditions [23].
A recent study showed that although pharmacy acqui-
sition costs of warfarin are lower than subcutaneous anti-
coagulant drugs, the total 6-month costs were lower with
subcutaneous anticoagulant drugs. Therefore, the initial
savings may be oﬀset by a higher incidence of venous
thromboembolic events and higher 6-month medical costs
with warfarin [24].
The use of ASA remains controversial. It is important to
notethatASAisanantiplateletandnotananticoagulant,but
some clinicians consider it to have a role in the prevention of
fatal PE and its use is recommended by the AAOS [5]f o r
the prevention of PE only, not for DVT. They recommend4 Thrombosis
that for patients at standard risk of both PE and major
bleeding, who represent the majority of patients undergoing
total joint arthroplasty, ASA (325mg twice daily, or 81mg
once daily if gastrointestinal symptoms develop, for 6 weeks)
may be one of the prophylactic drugs considered, along with
warfarin, LMWH, and fondaparinux. The guidelines do not
address other venous thromboembolic events, such as DVT,
and do not deﬁne standard or increased risk of bleeding or
PE. ASA has been shown to reduce venous thromboembolic
events by 26% and 13% (relative risk reductions) in patients
undergoingTHAandTKA,respectively(Table 1)[15],which
is less than the reduction with other prophylactic agents.
2.3. New Oral Anticoagulants. The ideal anticoagulant needs
to be more eﬀective without increasing bleeding risk, safe,
convenient to use, administered orally once daily and have
ﬁxed dosing—factors that could potentially improve patient
compliance. The most promising new oral anticoagulants
are the direct thrombin inhibitors (such as dabigatran) and
the direct Factor Xa inhibitors (such as rivaroxaban and
apixaban)—agents that directly target a single coagulation
factor in the coagulation cascade (Figure 1). Dabigatran is
approved in the EU and Canada (110mg within 1–4 hours
of surgery, then 220mg once daily for 28–35 days after THA
and 10 days after TKA) for VTE prophylaxis after elective
THA/TKA in adults [25]. Rivaroxaban is approved in the EU
and numerous other countries for the prevention of VTE in
adult patients after elective hip or knee arthroplasty (10mg
6–10 hours after surgery, then once daily for 35 days after
THA and 14 days after TKA [26]). These two drugs represent
the ﬁrst new oral agents for VTE prophylaxis in THA and
T K Ai no v e r5 0y e a r s .
2.3.1. Apixaban. Apixaban is an oral, direct Factor Xa in-
hibitor with predictable pharmacokinetics and pharmaco-
dynamics [27]. Gender has no clinically relevant eﬀect on
apixaban [28]. Data are lacking for the eﬀects of body weight
or old age on apixaban. Approximately half of administered
apixaban is absorbed and half is recovered in faeces. Of the
total dose, approximately one-third is recovered in urine, of
which over 80% is apixaban [29].
Digoxin and inhibitors or substrates of P450 enzymes
do not have clinically relevant interactions with apixaban
[30, 31]. Absorption of apixaban is not aﬀected after a high-
c a l o r i em e a l[ 32].
A phase II study [33] of apixaban was used to establish
the dose to be used for the phase III clinical development
programme. In this study, 1,238 patients were randomized
to one of six double-blind apixaban doses (5, 10 or 20mg
once daily or 2.5, 5 or 10mg twice daily), enoxaparin (30mg
twice daily) or open-label warfarin (titrated to an INR of
1.8–3.0), for 10–14 days. The primary eﬃcacy outcome (the
composite of VTE and all-cause mortality) decreased with
increasing apixaban dose (P = .09 for once-daily or twice-
daily regimens combined,P = .19 for once-daily and P = .13
for twice-daily dosing). There was a signiﬁcant dose-related
increase of total adjudicated bleeding events for the once-
daily (P = .01) and twice-daily (P = .02) regimens. The
authors concluded that apixaban 2.5mg twice daily and 5
mg once daily might have a promising risk–beneﬁt proﬁle
compared with enoxaparin 30mg twice daily and warfarin.
The ADVANCE-1 phase III study compared apixaban
2.5mg twice daily with the enoxaparin regimen commonly
used in North America of 30mg twice daily, for the preven-
tionofVTEafterTKA(N =3,195)[34].Theprimaryeﬃcacy
outcome (composite of venographic DVT, symptomatic,
objectively conﬁrmed DVT or nonfatal PE, or death from
any cause) occurred in 9.0% of patients receiving apixaban
and 8.8% of patients receiving enoxaparin (relative risk
1.02, 95% conﬁdence interval [CI] 0.78 to 1.32, P = .06
for noninferiority, statistical criteria not met) during the
treatment period. The rates of PE were 1.0% in the apixaban
group and 0.4% in the enoxaparin group; two PEs were
fatal in the apixaban group and none were fatal in the
enoxaparin group. Major or clinically relevant nonmajor
bleeding occurred in 2.9% and 4.3% of patients receiving
apixaban and enoxaparin, respectively (P = .03). Major
bleeding occurred in 0.7% and 1.4% of patients receiving
apixaban and enoxaparin, respectively (P = .053). One
patient in the enoxaparin group died from bleeding; none of
the apixaban group died from bleeding. In the ADVANCE-
2 study, which compared apixaban 2.5mg twice daily with
enoxaparin 40mg once daily (also in patients undergoing
TKA; N = 3,057), the hypothesis was that apixaban would
be noninferior to enoxaparin based on a prespeciﬁed margin
for the primary eﬃcacy outcome in which the upper limit of
the two-sided 95% CI is <1.25 for relative risk and <5.6% for
the absolute risk diﬀerence [35]. If both criteria were met,
superiority was tested. The primary eﬃcacy endpoint (the
same as in ADVANCE-1) occurred in 15.1% of the apixaban
group and 24.4% of the enoxaparin group (relative risk 0.62,
95% CI 0.51 to 0.74, P<. 0001 for noninferiority and
superiority; absolute risk diﬀerence −9.3%, 95% CI −12.7 to
−5.8, P<. 0001 for noninferiority). Two patients receiving
apixaban died from PE and one patient receiving enoxaparin
died from bleeding. Major or clinically relevant nonmajor
bleeding occurred in 3.5% of the apixaban group and 4.8%
of the enoxaparin group (P = .09). In summary, the ﬁndings
of these studies suggest that apixaban is signiﬁcantly more
eﬀective than the 40mg once-daily enoxaparin regimen at
reducing the composite of DVT, PE and death by any cause,
with no increased risk of major bleeding. In ADVANCE-1,
apixaban did not meet the prespeciﬁed statistical criteria for
noninferiority of eﬃcacy compared with enoxaparin 30mg
twice daily.
2.3.2. Dabigatran Etexilate. Dabigatran is an oral, once-
daily, direct thrombin inhibitor that can be given in a ﬁxed
oral dose without dose adjustment for age, body weight or
gender [36, 37]. It has a rapid onset of action and provides
predictable anticoagulation without the need for routine
coagulation monitoring [36]. The main elimination pathway
is renal excretion, accounting for more than 80% of the
systemically available dose of dabigatran [38].
Therapeutic doses of dabigatran are unlikely to interact
with drugs that are metabolized by the CYP450 system [38].
It has been shown that food delays the time to peak plasmaThrombosis 5
concentration by 2 hours, but does not have a relevant eﬀect
on the extent of dabigatran absorption [39].
Dose-ranging studies in patients undergoing THA sug-
gested that the therapeutic window was 12.5–300mg twice
daily (BISTRO I [40]) and in patients undergoing THA and
TKA the optimal total daily dose was 100–300mg (BISTRO
II [41]).
Two phase III, randomized trials in patients undergoing
TKA have been conducted, one with most of its participating
centres in the EU and one in North America, comparing
dabigatran with enoxaparin. In the European study (RE-
MODEL; N = 2,101 [42, 43]), once-daily dabigatran (ﬁrst
dose was half of the subsequent dose; subsequent doses were
150mg and 220mg in two tablets) was as eﬀective (nonin-
ferior) as once-daily enoxaparin (40mg) for preventing VTE
and all-cause mortality in patients undergoing TKA (40.5%
of the dabigatran 150mg group [absolute risk diﬀerence
versus enoxaparin 2.8%], 36.4% of the dabigatran 220mg
group [absolute risk diﬀerence versus enoxaparin −1.3%]
and 37.7% of the enoxaparin group), with similar bleeding
rates (compared with enoxaparin: P = 1.0 for the dabigatran
150mg dose and P = .082 for the dabigatran 220mg dose).
However, in the RE-MOBILIZE study (N = 2,615) [43, 44],
which used the usual North American enoxaparin regimen
of 30 mg twice daily, dabigatran 150mg and 220mg showed
inferior eﬃcacy to enoxaparin for the primary outcome of
total VTE and death (33.7% of the 150mg group [absolute
risk diﬀerence versus enoxaparin 8.4%, P = .0009 for
noninferiority versus enoxaparin], 31.1% of the dabigatran
220mg group [absolute risk diﬀerence versus enoxaparin
5.8%, P = .0234] and 25.3% of the enoxaparin group),
althoughbleedingratesweresimilarbetweenallthreegroups
(0.6% of the 150mg group, 0.6% of the 220mg group and
1.4% of the enoxaparin group). The secondary outcome of
major VTE (deﬁned as proximal DVT, PE and VTE-related
death) occurred in 3.0% of the dabigatran 150mg group
(risk diﬀerence with enoxaparin 0.8%, P = .36), 3.4% of the
dabigatran 220mg group (risk diﬀerence with enoxaparin
1.2%, P = .21) and 2.2% of the enoxaparin group.
The RE-NOVATE study compared once-daily dabigatran
220mg or 150mg with once-daily enoxaparin 40mg after
THA (N = 3,494). Both doses of dabigatran were noninferior
to enoxaparin for the composite of total VTE and death
(8.6% of the 150mg group [absolute risk diﬀerence versus
enoxaparin 1.9%, P<. 0001 for noninferiority versus enoxa-
parin], 6.0% of the 220mg group [absolute risk diﬀerence
versus enoxaparin −0.7%, P<. 0001 for noninferiority
versusenoxaparin]and6.7%oftheenoxaparingroup).Rates
of major bleeding did not diﬀer signiﬁcantly between the
groups (1.3% for the 150mg group [P = .60], 2.0% for
the 220mg group [P = .44] and 1.6% for the enoxaparin
group). There were no signiﬁcant diﬀerences in cardiac
events or liver enzyme elevations in any of the three groups
[43, 45]. Whereas RE-MODEL and RE-NOVATE showed the
tested doses of dabigatran were noninferior to the 40-mg
enoxaparin regimen for VTE prophylaxis, RE-MOBILIZE
found dabigatran to be inferior to the 30-mg twice-daily
enoxaparin regimen. Possible reasons for this ﬁnding are
the higher daily dosage of enoxaparin and longer treatment
duration in the RE-MOBILIZE study compared with the RE-
MODEL study.
A meta-analysis of the three dabigatran studies (which
assessed the recommended 220mg dose) supported the
ﬁndings of RE-MODEL and RE-NOVATE [46]. It showed
that there were no signiﬁcant diﬀerences between dabigatran
220mg and enoxaparin in any endpoints when RE-MODEL
and RE-NOVATE were analysed (P>. 15), or when all three
trials were included in the analysis (all P>. 30). Risk ratios
(random eﬀects) for the composite of total VTE and all-
cause mortality were 0.95 (95% CI 0.82 to 1.10) in the two-
trial analysis and 1.05 (95% CI 0.87 to 1.26) in the three-
trial analysis. Major bleeding rates did not diﬀer signiﬁcantly
when RE-MODEL and RE-NOVATE were analysed (P = .41
for random-eﬀects and ﬁxed-eﬀects analyses) or when all
three studies were analysed (P = .85 for random-eﬀects and
P = .95 for ﬁxed-eﬀects analyses).
In a recent prespeciﬁed pooled analysis of the studies, the
primary outcome (composite outcome of major and VTE-
related mortality) occurred in 3.3% of the enoxaparin group,
3.8%ofthe150mggroup(riskdiﬀerence0.5%,95%CI −0.6
to 1.6, I2 = 0% [if I2 was greater than 50%, heterogeneity was
considered to be substantial]) and 3.0% of the dabigatran
220mggroup(riskdiﬀerenceversusenoxaparin−0.2%,95%
CI −1 . 3t o0 . 9 ,I 2 = 37%). Rates of major bleeding were 1.4%
in the enoxaparin group, 1.1% in the 150mg group (risk
diﬀerence −0.4%, 95% CI −1.0 to 0.2, I2 = 0%) and 1.4% in
the dabigatran 220mg group (risk diﬀerence −0.2%, 95% CI
−0.8to0.5,I2 =40%).Theseﬁndingssuggestthatdabigatran
was as eﬀective as enoxaparin and the risk of major bleeding
was similar [47].
2.3.3. Rivaroxaban. Rivaroxaban—an oral, direct Factor Xa
inhibitor—was found to exhibit a predictable pharmacoki-
netic and pharmacodynamic proﬁle and does not require
doseadjustmentforage,gender[48]orweight[49].Rivarox-
aban and its metabolites have a dual route of elimination:
one-third of the administered drug is cleared as unchanged
active drug by the kidneys; one-third is metabolized to
inactive metabolites and then excreted by the kidneys; and
one-third is metabolized to inactive metabolites and then
excreted by the faecal route [50].
Rivaroxaban has a low propensity for drug–drug inter-
actions with frequently used concomitant medications, such
as naproxen [51], ASA [52] or clopidogrel [53], and no
interaction with the cardiac glycoside digoxin [54]. Dietary
restrictionsarenotnecessaryandrivaroxabanwasgivenwith
or without food in the phase III VTE prevention studies
(RECORD1–4 [REgulation of Coagulation in ORthopaedic
surgery to prevent Deep vein thrombosis and pulmonary
embolism]).
Phase II studies [55–58] showed that all investigated
rivaroxaban dose regimens had similar eﬃcacy to enoxa-
parin, and the incidence of major bleeding was not signiﬁ-
cantly diﬀerent to enoxaparin across a fourfold dose range
(5–20mg total daily rivaroxaban dose).
The RECORD programme comprised four phase III
studies investigating the eﬃcacy and safety of rivaroxaban
in 12,500 patients undergoing THA and TKA [59–62]. All6 Thrombosis
patients received rivaroxaban 10mg once daily 6–8 hours
after surgery, and there was no upper age or weight limit
for participation. The primary eﬃcacy endpoint was the
composite of DVT, nonfatal PE and all-cause mortality up
to day 30–42 after surgery for RECORD1 and RECORD2,
up to day 13–17 for RECORD3 and up to day 17 for
RECORD4. The main safety endpoint was the incidence
of treatment-emergent (observed no later than 2 days after
the last dose of the study drug) major bleeding events.
Other safety outcomes (for example, nonmajor bleeding and
postoperative wound infection) were also reported [59–62].
RECORD1 showed that 5 weeks of extended-duration
rivaroxaban (10mg once daily for 31–39 days after surgery)
was signiﬁcantly more eﬀective than enoxaparin (40mg once
daily for 31–39 days) for extended-duration prophylaxis in
patients undergoing THA (1.1% versus 3.7% for the primary
eﬃcacy endpoint, P<. 001) [59]. Major bleeding events did
notdiﬀersigniﬁcantlybetweenthegroups(0.3%versus0.1%
of patients, P = .18). Clinically relevant nonmajor bleeding
occurred in 2.9% of the rivaroxaban group versus 2.4% of
the enoxaparin group; haemorrhagic wound complications
in 1.5% versus 1.7% of patients; and postoperative wound
infections in 0.4% of patients in both groups. The incidence
of symptomatic VTE during treatment was not signiﬁcantly
diﬀerent between the groups (0.3% versus 0.5%, P = .22).
RECORD2 demonstrated that extended-duration
rivaroxaban prophylaxis (10mg once daily for 31–39
days after surgery) was signiﬁcantly more eﬀective than
short-duration prophylaxis with enoxaparin (40 mg once
daily for 10–14 days) followed by placebo in patients
undergoing THA (2.0% versus 9.3% for the primary eﬃcacy
endpoint, P<. 0001) [60]. The incidence of bleeding was
comparable between extended-regimen rivaroxaban and
short-duration enoxaparin. Major bleeding events occurred
in <0.1% of patients in both groups. Clinically relevant
nonmajor bleeding was recorded in 3.3% of the rivaroxaban
group versus 2.7% of the enoxaparin group; haemorrhagic
wound complications in 1.6% versus 1.7% of patients;
and postoperative wound infections in 0.7% versus 0.5%
of patients, respectively. Signiﬁcantly fewer patients in the
rivaroxaban group had symptomatic VTE (0.2%) than in the
enoxaparin group (1.2%, P = .004) during the active study
period.
InRECORD3,rivaroxabanprophylaxis(10mgoncedaily
for 10–14 days) was signiﬁcantly more eﬀective than the
European enoxaparin regimen for prophylaxis (40mg once
daily) in patients undergoing TKA (9.6% versus 18.9% for
the primary eﬃcacy endpoint, P<. 001), with a similar
safetyproﬁle[61].Ratesofmajorbleedingweresimilarinthe
rivaroxaban and enoxaparin groups (0.6% versus 0.5%, P =
.77); clinically relevant nonmajor bleeding occurred in 2.7%
versus 2.3% of patients; haemorrhagic wound complications
in 2.0% versus 1.9% of patients; and postoperative wound
infections in 0.6% versus 0.9% of patients. There was a
signiﬁcant reduction in the number of symptomatic venous
thromboembolic events in the rivaroxaban group (0.7%
versus 2.0%, P = .005).
In RECORD4, rivaroxaban showed signiﬁcantly better
eﬃcacy than the enoxaparin regimen (30mg every 12
hours) commonly used in North America for short-term
prophylaxis after TKA (6.9% versus 10.1%, respectively, for
the primary eﬃcacy endpoint, P = .0118) [62]. The rates
of major bleeding were 0.7% versus 0.3% (P = .1096),
respectively; clinically relevant nonmajor bleeding occurred
in 2.6% versus 2.0% of patients; haemorrhagic wound
complications in 1.4% versus 1.5% of patients; and postop-
erative wound infections in 0.3% versus 0.2% of patients,
respectively.TheobservedincidencesofsymptomaticVTEin
those receiving rivaroxaban or enoxaparin were 0.7% versus
1.2% (P = .187), respectively.
In the four studies comparing rivaroxaban with enoxa-
parin, rivaroxaban demonstrated superior eﬃcacy compared
with enoxaparin. In addition, extended thromboprophylaxis
with rivaroxaban was signiﬁcantly more eﬀective than short-
term enoxaparin plus placebo in the prevention of total,
major and symptomatic VTE after THA. Furthermore,
the incidence of treatment-emergent major and clinically
relevant nonmajor bleeding was low for rivaroxaban and
enoxaparin (P = .21 [data on ﬁle] for RECORD1, P = .39
[data on ﬁle] for RECORD2, P = .44 for RECORD3 [61]
and P = .18 for RECORD4 [62]). There was no evidence
of compromised liver function or rebound cardiovascular
events associated with rivaroxaban.
In a pooled analysis of the RECORD1, 2 and 3 studies
(which compared rivaroxaban with enoxaparin 40 mg once
daily after THA and TKA) [63], the prespeciﬁed primary
eﬃcacy outcome (the composite of symptomatic VTE [DVT
or PE] and all-cause mortality at 2 weeks) was 0.4% and
0.8%, respectively (P = .005). The rates were 0.5% and
1.3%, respectively, at the end of the planned medication
period (P<. 001). Rates of on-treatment major bleeding
were 0.2% for both drugs at 2 weeks (P = .662), and 0.3%
for rivaroxaban and 0.2% for enoxaparin at the end of the
planned medication period (P = .305). Rates of clinically
relevant nonmajor bleeding were 2.6% for rivaroxaban and
2.3% for enoxaparin at 2 weeks, and 3.0% and 2.5%,
respectively, at the end of the planned medication period (P-
values not reported).
In a pooled analysis of all four RECORD studies [64], the
primary eﬃcacy endpoint (the composite of symptomatic
VTE [DVT or PE] and death) was signiﬁcantly reduced
for the rivaroxaban regimens compared with enoxaparin
regimens at day 12 ± 2 (0.5% versus 1.0%, P = .001), in
the planned treatment period (0.6% versus 1.3%, P<. 001),
and in a post hoc analysis of the treatment and follow-up
period (0.8% versus 1.6%, P<. 001). Rates of treatment-
emergent major bleeding were not signiﬁcantly diﬀerent
between groups at any of the time points analysed [64].
The composite of major and clinically relevant nonmajor
bleeding did not diﬀer at day 12 ± 2( P = .186), but
was signiﬁcantly higher for rivaroxaban in the planned
medication period (P = .039). Rates of the composite of
PE and death were lower for rivaroxaban compared with
enoxaparin in the planned treatment period and follow-up
(0.5% versus 0.8%, P = .039) [65].
Future research needs to assess whether changing the
timing of the ﬁrst dose could improve the safety proﬁle
without signiﬁcantly aﬀecting eﬃcacy. In theory, the earlierThrombosis 7
an anticoagulant is given, the better the eﬃcacy, but at
a cost of increased bleeding [66]. Conversely, the longer
anticoagulation is delayed, the lower the risk of bleeding, but
eﬃcacy may decrease too.
3. Summary and Conclusions
Among the numerous oral anticoagulants currently in phase
II and III development, three of the oral agents—apixaban,
dabigatran and rivaroxaban—hold considerable potential
beneﬁts for improving thromboprophylaxis strategies. In
light of recent promising ﬁndings, more studies on direct
thrombin inhibitors and Factor Xa inhibitors are likely. In
addition, reports from daily clinical practice will indicate
whether the new agents will change current practice [67]. A
phase III TKA study has shown that apixaban is signiﬁcantly
more eﬀective than the once-daily enoxaparin regimen,
without an increase in bleeding. The phase III studies
comparing dabigatran with enoxaparin were designed to
show the noninferiority of dabigatran. It was found that
dabigatran has similar eﬃcacy and safety compared with
the once-daily enoxaparin regimen in THA and TKA. In
addition,phaseIIIstudieshaveshownsigniﬁcantlyimproved
eﬃcacy and similar safety for rivaroxaban compared with
both once-daily and twice-daily enoxaparin regimens in
THA and TKA. All of these agents provide the beneﬁt of oral
dosing without the need for monitoring or dose adjustment,
thereby improving the convenience of prophylaxis.
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